2016 Leads Side effects 
World of DTC Marketing
JUNE 1, 2021
Since that time, Biogen’s MS drugs have faced intense competition as MS patients continue to vent on social media that the Biogen drug has nasty side effects. Biogen concluded the key to effectiveness was giving patients a high-enough dose, but critics howled, with one calling the analysis “a post hoc dumpster dive operation.”
pharmaphorum
AUGUST 11, 2022
In 2016, the estimated annual cost of drug-related morbidity and mortality resulting from non-optimised medication therapy was $528.4 This means that hyper-metabolisers would need their dosage to be increased to achieve the desired effect. billion in the United States alone.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Clarivate
JANUARY 3, 2023
Starting with 12,160 Research Fronts, representing papers published and cited between 2016 and 2021, the next step was to select the fronts containing core literature that is both highly cited and recent – an indicator of particularly active and fast-moving research. Fields and nations.
European Pharmaceutical Review
JULY 5, 2022
There is an urgent need for more effective chemotherapy treatments with less severe toxicity and side effects. Irinotecan – also known by the brand name Campto/Camptosar ® (Pfizer Ltd.) – has proven to be an effective chemotherapy agent against several types of gastrointestinal cancer. 5): V38-V49.
European Pharmaceutical Review
DECEMBER 14, 2023
Our research showed that in Europe between 1999 and 2016, 35 products were withdrawn. Samantha leads study design and statistical analysis and has experience with the CPRD electronic health records database. 1,2 This signals a promising trend towards a more comprehensive and diversified approach in regulatory decision-making.
European Pharmaceutical Review
JUNE 12, 2024
The specific representation of these events differed between the treatments, highlighting potential differences in side effect profiles that should be explored in further studies. 2016; 46: 479–93. Adverse events were relatively low in both groups (2.22 percent for MBK-01 and 4.26 percent for fidaxomicin). Intern Med J.
European Pharmaceutical Review
NOVEMBER 4, 2022
based treatment concomitant with reductions in traditionally unavoidable and problematic side effects. Patient Preference and Adherence, 2016. FDA Feedback Leads to Discontinuation of Tesetaxel Development in Solid Tumors [Internet]. The importance of taxanes in oncology. Volume 10, pp.1609–1621. 1609–1621. Karlovitch S.
Expert insights. Personalized for you.
187 
Let's personalize your content